RxDoctor Payments Data

Ajay Jain, MD

Gastroenterology · Indianapolis, INNPI 1023067477

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $378,419 of the $432,480 with a category attached, or 87.5%. It is spread thinly across 27 manufacturers, the largest accounting for just 22.6%. Among gastroenterology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$432,480in general payments, 2019–2025

Across 676 payments — averaging $639.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$98K
  • Pfizer$95K
  • Phathom Pharmaceuticals, Inc.$67K
  • Johnson & Johnson$66K
  • E.r. Squibb & Sons, L.L.C.$35K
  • Intercept Pharmaceuticals, Inc.$23K
  • plus $48K from 21 others

What the payments were for

  • Consulting fees$7,4302%
  • Speaking & faculty fees$378,41987%
  • Travel & lodging$30,1387%
  • Food & beverage$16,4024%
  • Education$170%
  • Gifts$730%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$432,480 in reported general payments places this provider in the 95th percentile of 323 gastroenterology providers in Indiana.

See all gastroenterology providers in Indiana

Medicare billing

Part B allowed, 2024
$100,869
Medicare patients
379
Services billed
870

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab26$188,858
LinzessLinaclotide72$67,136
ViberziEluxadoline12$22,278
Mesalamine26$18,864
Dexlansoprazole DrDexlansoprazole37$9,593
Budesonide EcBudesonide12$8,878
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates81$4,789
Pantoprazole Sodium103$4,517
Ursodiol12$3,619
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl220$2,938
Promethazine Hcl26$2,472
Omeprazole198$2,042
SutabSod Sulf/Pot Chloride/Mag Sulf12$1,982
Dicyclomine Hcl70$1,715
Esomeprazole Magnesium21$1,647

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Viberzi$97,650$89,41484 claims
Braintree Laboratories, Inc.Sutab$73$1,98212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 323 gastroenterology providers in Indiana.

Other gastroenterology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →